Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: A multicentre, retrospective, 3-year study

Nephrology

Volumn 19, Issue 2, 2014, Pages 84-93

  Torregrosa, Jose Vicente ^a   Morales, Enrique ^b   Díaz, Juan Manuel ^c   Crespo, Josep ^d   Bravo, Juan ^e   Gõmez, Gonzalo ^f   Gentil, Miguel Ángel ^g   Rodríguez Benot, Alberto ^h   García, Minerva Rodríguez ⁱ   Jiménez, Verõnica Lõpez ^j   Gutiérrez Dalmau, Alex ^k   Jimeno, Luisa ^l   Sáez, María José Pérez ^m   Romero, Rafael ⁿ   Gõmez Alamillo, Carlos ^o  

^a HOSPITAL CLÍNIC   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^k HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁿ Instituto de Salud Carlos III   (Spain)

^o HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

calcium; cinacalcet; parathyroid hormone; renal transplantation; secondary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHORUS; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; COLITIS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SPAIN; TREATMENT OUTCOME;

CALCIUM; CINACALCET; PARATHYROID HORMONE; RENAL TRANSPLANTATION; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; CALCIUM; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RETROSPECTIVE STUDIES;

EID: 84892549204     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12186     Document Type: Article

References (47)

1. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y,. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol. Dial. Transplant. 2004; 19: 1281-1287.
2. Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 1998; 54: 1704-1713.
3. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS,. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin. Transplant. 2007; 21: 558-566.
4. Morales E, Gutierrez E, Andres A,. Treatment with calcimimetics in kidney transplantation. Transplant. Rev. 2010; 24: 79-88.
5. Lee PP, Schiffmann L, Offermann G, Beige J,. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press. Res. 2004; 27: 191-196.
6. Chou FF, Lee CH, Chen HY, Chen JB, Hsu KT, Sheen-Chen SM,. Persistent and recurrent hyperparathyroidism after total parathyroidectomy with autotransplantation. Ann. Surg. 2002; 235: 99-104.
7. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am. J. Transplant. 2008; 8: 803-810.
8. Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant. Proc. 2009; 41: 2139-2143.
9. Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G,. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86: 919-924.
10. Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G,. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am. J. Nephrol. 2010; 31: 482-489.
11. Schwarz A, Merkel S, Leitolf H, Haller H,. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation 2011; 91: 560-565.
12. Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant. Proc. 2009; 41: 2394-2395.
13. Kamar N, Gennero I, Spataru L, et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: Once- versus twice-daily dose. Nephrol. Dial. Transplant. 2008; 23: 3720-3726.
14. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM,. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008; 86: 413-417.
15. Borstnar S, Erzen B, Gmeiner Stopar T, et al. Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients. Transplant. Proc. 2010; 42: 4078-4082.
16. Apostolou T, Kollia K, Damianou L, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant. Proc. 2006; 38: 3514-3516.
17. Toro Prieto FJ, Bernal Blanco G, Navarro Garcia M, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant. Proc. 2009; 41: 2144-2147.
18. Carrasco FR, Perez-Flores I, Calvo N, Ridao N, Sanchez A, Barrientos A,. Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure. Transplant. Proc. 2009; 41: 2385-2387.
19. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol. Dial. Transplant. 2007; 22: 577-583.
20. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675-680.
21. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG,. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. 2005; 20: 1311-1314.
22. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG,. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. 2007; 22: 2362-2365.
23. Copley JB, Germain M, Stern L, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant. Proc. 2010; 42: 2503-2508.
24. Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin. J. Am. Soc. Nephrol. 2006; 1: 323-326.
25. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549.
26. Cho ME, Duan Z, Chamberlain CE, Reynolds JC, Ring MS, Mannon RB,. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant. Proc. 2010; 42: 3554-3558.
27. Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am. J. Transplant. 2006; 6: 2391-2395.
28. Guerra R, Auyanet I, Fernandez EJ, et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: Analysis after a year with cinacalcet. J. Nephrol. 2011; 24: 78-82.
29. Courbebaisse M, Diet C, Timsit MO, et al. Effects of cinacalcet in renal transplant patients with hyperparathyroidism. Am. J. Nephrol. 2012; 35: 341-348.
30. Paschoalin RP, Torregrosa JV, Barros X, Duran CE, Campistol JM,. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: Long-term follow-up and effect of withdrawal. Transplant. Proc. 2012; 44: 2376-2378.
31. Pinho LR, Ribeiro Santos MJ, Pestana Vasconcelos M,. Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation. Clin. Nephrol. 2011; 75: 263-268.
32. Paschoalin RP, Torregrosa JV, Sanchez-Escuredo A, Barros X, Duran CE, Campistol JM,. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: A long-term follow-up. Transplant. Proc. 2012; 44: 2588-2589.
33. Yang RL, Freeman K, Reinke CE, et al. Tertiary hyperparathyroidism in kidney transplant recipients: Characteristics of patients selected for different treatment strategies. Transplantation 2012; 94: 70-76.
34. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP,. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. 2005; 20: 1315-1319.
35. Apostolou T, Damianou L, Kotsiev V, Drakopoulos S, Hadjiconstantinou V,. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin. Nephrol. 2006; 65: 374-377.
36. Bergua C, Torregrosa JV, Cofan F, Oppenheimer F,. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant. Proc. 2007; 39: 2254-2255.
37. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism (number for clinicaltrials.gov: NCT00975000). [Cited 19 July 2012.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00975000.
38. Torregrosa JV, Bover J, Cannata Andia J, et al. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D. Nefrologia 2011; 31 (Suppl 1): 3-32.
39. Gentil MA, Perez-Valdivia MA, Gonzalez-Roncero FM, et al. Treatment of anemia in renal transplantation: Impact of a stricter application of hemoglobin targets. Transplant. Proc. 2008; 40: 2916-2918.
40. Morales JM, Marcen R, Andres A, et al. Renal transplantation in the modern immunosuppressive era in Spain: Four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int. Suppl. 2008; 111: S94-99.
41. Sprague SM, Josephson MA,. Bone disease after kidney transplantation. Semin. Nephrol. 2004; 24: 82-90.
42. Evenepoel P, Van Den Bergh B, Naesens M, et al. Calcium metabolism in the early posttransplantation period. Clin. J. Am. Soc. Nephrol. 2009; 4: 665-672.
43. Choncol MWR,. Potential future uses of calcimimetics in patients with chronic kidney disease. Nephrol. Dial. Transplant Plus 2008; 1: i36-41.
44. Torregrosa JV, Bergua C, Martinez de Osaba MJ, Oppenheimer F, Campistol JM,. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transplant. Proc. 2009; 41: 2396-2398.
45. Jadoul M, Banos A, Zani VJ, Hercz G,. The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus 2010; 3: 37-41.
46. Bover J, Perez R, Molina M, et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: An observational study in routine clinical practice. Nephron Clin. Pract. 2011; 118: c109-121.
47. Spanish Society of Nephrology. Renal Disease Patients Registry. 2009 Report. [Cited 19 July 2012.] Available from URL: http://www.senefro.org/ modules.php?name=webstructure&idwebstructure=128.